Business Wire · Dec 2025
Reported NSCLC validation data across 1,487 samples and positioned OncoPrism-NSCLC as a predictive biomarker for ICI benefit.
Cofactor closes the precision medicine gap with predictive diagnostics
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Cofactor Genomics is a commercial-stage biotechnology company focused on RNA-based predictive diagnostics for oncology, especially predicting patient response to immunotherapy. Its flagship product is OncoPrism, a machine-learning/RNA assay used in the PREDAPT clinical program and supported by CAP/CLIA laboratory operations.
Primary product
OncoPrism immunotherapy-response diagnostic
Founded
2015
Headquarters
St. Louis, Missouri, United States
Team size
1-10
Industry
Biotechnology
Sub-industry
Oncology diagnostics
Offices
St. Louis, Missouri, United States
San Francisco, California, United States
Cambridge, Massachusetts, United States
Business model
clinical diagnostics
laboratory testing services
research-use-only assays
clinical trial collaborations
Funding
Stage
commercial-stage / venture-backed
Total raised
$29.2M
Latest round
Strategic investment · Dec 2025
Dec 2025 · Labcorp and Ascension Ventures
Seed / Venture - Series Unknown
Aug 2023
Dec 2021
Sep 2017 · Menlo Ventures
Jul 2015 · Y Combinator
Jun 2010 · NIH
People & investors
Leadership
Chief Executive Officer
President & CTO
Medical Director
Vice President of Translational Science
Work & culture
Mission-driven, scientific, fast-moving, and collaborative, with a strong experimentation mindset and team-building/community-service culture.
Benefits
medical insurance
dental insurance
vision insurance
HSA
401(k) matching
commuter benefits
dog-friendly office
inclusive culture
Product & market
Pricing
B2B diagnostics and lab-services model; research-use-only products and sponsored study programs are offered, but public pricing is not disclosed.
Differentiators
- —RNA-based predictive immune modeling
- —multidimensional biomarkers rather than single-analyte biomarkers
- —FFPE solid-tumor biopsy compatibility
- —CAP/CLIA laboratory with Medicare coverage
- —designed to predict immunotherapy response
Technology
RNA sequencing
machine learning
Predictive Immune Modeling
Health Expression Models
OncoPrism assay
FFPE tumor biopsy analysis
CAP/CLIA laboratory
Customers
healthcare systems
oncologists
pathologists
clinical researchers
pharma and biotech partners
CROs
Competitors
Tempus
Foundation Medicine
Guardant Health
Caris Life Sciences
Personalis
Scale & contact
Estimated revenue
USD 10M-20M estimated by one public company data source; another public estimate is ~$3.2M ARR, so public estimates conflict.
Estimated monthly visits
3.3K
Traffic estimate as of Dec 2025
Latest news
Business Wire · Dec 2025
Announced strategic investments from Labcorp and Ascension Ventures to accelerate nationwide expansion of OncoPrism and broaden patient access.
Business Wire · Jan 2025
Chris Parker became CEO and Jarret Glasscock shifted to President/CTO as the company moved toward commercialization.
Business Wire · Nov 2024
Published PREDAPT HNSCC validation showing improved specificity and predictive performance versus PD-L1 and TMB.
Business Wire · Oct 2024
Palmetto GBA granted national Medicare coverage for OncoPrism in recurrent/metastatic head and neck squamous cell carcinoma.
Jobs and careers at Cofactor Genomics
0 jobs at Cofactor Genomics
No open positions
Check back later for new openings